CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 177 enrolled
Drug / intervention
efavirenz +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01075152
NCT01075152Phase 4Completed
CompareCT.gov

Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis

University of Minnesota·interventional·Posted Feb 24, 2010·Updated Jun 9, 2020

In Brief

A Phase 4 clinical trial evaluating efavirenz and nucleoside for Cryptococcal Meningitis and 2 related conditions. Completed, enrolled 177 participants across 3 sites in 2 countries.

Detailed Summary

The Cryptococcal Optimal ART Timing (COAT) trial seeks to determine after cryptococcal meningitis (CM) whether early initiation of antiretroviral therapy (ART) prior to hospital discharge results in superior survival compared to standard initiation of ART started as an outpatient.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCryptococcal Meningitis, HIV Infections, AIDS
CountriesSouth Africa, Uganda
CollaboratorsMbarara University of Science and Technology, Makerere University, National Institute of Allergy and Infectious Diseases (NIAID), University of Cape Town

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 24, 2010
Enrollment StartNov 1, 2010
Primary CompletionOct 1, 2012
Study CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 16.4 years ago

Interventions

efavirenzdrug

Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.

nucleosidebiological

Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.